Pre-market hot trades in US stocks: LogProstyle pre-market down 7.14%; Nebius pre-market up 3.34%

Pre-market Hot Trades in US Stocks

LogProstyle is down 7.14% in pre-market trading. Based on recent key news:

1. On July 14, LogProstyle surged over 46% during the trading session, as the company announced its FY26 financial report showing a 7.6% increase in revenue and declared a dividend, driving the stock price higher. The trading volume reached 82.1973 million shares, with a fluctuation range of $1.100-$1.390. Source: Zhitong Finance

2. On July 13, LogProstyle announced a quarterly cash dividend of $0.046 per share, totaling $1.09 million, with the first payment scheduled for August 31. This news boosted investor confidence. Source: Business Wire

3. On July 13, LogProstyle's CEO stated that the company achieved steady revenue growth driven by its real estate and hotel businesses and improved operating margins through cost control. This statement further lifted market sentiment. Source: EDGAR The real estate and hotel sectors are experiencing steady growth, supported by a stable macroeconomic environment.

Nebius is up 3.34% in pre-market trading. Based on recent key news:

1. On July 14, Nebius signed a computing power agreement worth over $1 billion with Reflection AI. The agreement is effective until 2029, and Reflection AI will gain access to computing resources using NVIDIA GB300 AI chips. This news drove Nebius's stock price up about 3% in pre-market trading. Source: Golden Finance

2. On July 14, Morgan Stanley raised its forecast for capital expenditures of major US tech giants in 2026 to $80.5 billion. This indicates that the demand for AI computing power remains strong, further supporting Nebius's market performance. Source: Morgan Stanley

3. On July 14, after reaching an agreement with Reflection AI, Nebius's stock price rose to $219 in pre-market trading, reflecting market confidence in its future growth. Source: Benzinga Pro AI computing power demand is strong, with increased capital expenditures.

Top Gainers in Pre-market US Stocks

Jet.AI is up 954.80% in pre-market trading. Based on recent key news:

1. On July 13, Jet.AI completed its merger with flyExclusive, marking a significant development for both technology companies that could have a major impact on the market. The merger was completed after approval at a special shareholder meeting, indicating a positive market reaction to the deal.

2. On July 15, Jet.AI's earnings per share forecast was raised from $0.75 to $1.00. Although the revenue forecast was lowered from $2.23 million to $1.10 million, analysts still gave a buy rating, showing market confidence in its profitability On July 15, Jet.AI's stock price rose 21.56% in pre-market trading, reaching $5.92, reflecting the market's positive response to its recent financial performance and merger news. Mergers and acquisitions in the technology sector are increasing, leading to heightened market volatility.

VivoSim Labs rose 85.76% in pre-market trading. Based on recent news,

1. On July 15, VivoSim Labs announced that its revenue for fiscal year 2027 is expected to grow by over 500%, primarily due to increased demand for its drug safety testing services. This news significantly boosted the stock price.

2. On July 15, VivoSim Labs received a $5 million milestone payment from Eli Lilly to fund its mid-stage research on inflammatory bowel disease drugs. This payment further enhanced investor confidence.

3. On July 15, VivoSim Labs stated that its lab-cultured human tissue models help predict drug side effects and reduce reliance on animal testing. This technology has attracted gene therapy and antibody drug developers, enhancing the company's market position. The rising demand in the biotechnology sector has driven the stock price up.

Ernexa Therapeutics rose 54.95% in pre-market trading. Based on recent key news:

1. On July 15, an independent contract research organization successfully replicated ERNA-101 combination data in a larger-scale preclinical study. This achievement boosted the company's confidence in advancing its new drug research application (IND) process, significantly driving up the stock price.

2. On July 15, Ernexa issued a statement reminding investors to remain cautious regarding forward-looking statements; nevertheless, the market remains optimistic about its future developments, further pushing the stock price up. The biotechnology sector has been active recently, with noticeable capital inflows